Immunologic and non-immunologic loss of islet cells upon their transplantation into the liver leads to suboptimal outcomes. Anti-inflammatory agents are used during autologous and allogeneic transplantation. The aim of this qualitative systematic literature review is to evaluate their clinical use and safety. Electronic databases Embase, PubMed, Cumulative Index for Nursing and Allied Health Literature, ClinicalTrials.gov, and EU Clinical Trials Register were searched. Of the 216 unique citations, 10 with tumor necrosis factor (TNF) blockers [etanercept (ETA) or infliximab] and 3 with both TNF blockers and an interluekin-1 receptor antagonist [anakinra (ANA)]) were included. Of these, 12 were in allogeneic and one in autologous transplant. Insulin independence with decreased islet cells and number of transfusions were reported with their use. One infection was reported in a group receiving ETA. Analysis suggested that the use of ETA ± ANA have the potential to improve outcomes in islet cell transplant.

胰岛细胞移植入肝脏后，其免疫和非免疫损失会导致次优结果。抗炎药用于自体和异体移植过程中。本系统的定性文献综述的目的是评估其临床用途和安全性。检索了电子数据库Embase，PubMed，护理和相关健康文献累积索引，ClinicalTrials.gov和EU临床试验注册簿。在这216个独特的引文中，包括10个使用肿瘤坏死因子（TNF）阻断剂[依那西普（ETA）或英夫利昔单抗]和3个同时使用TNF阻断剂和interluekin-1受体拮抗剂[anakinra（ANA）]。其中，12例是同种异体的，1例是自体移植的。使用胰岛细胞减少和输血次数的胰岛素独立性已有报道。接受ETA治疗的人群中报告有一种感染。分析表明，ETA±ANA的使用可能会改善胰岛细胞移植的结局。